Spironolactone and Pregabalin Interaction: What Patients and Prescribers Need to Know

What Is the Spironolactone, Pregabalin Interaction?

Spironolactone and pregabalin do not share a metabolic pathway, so a traditional pharmacokinetic drug-drug interaction (enzyme inhibition, enzyme induction, transporter competition) does not apply here. The interaction is pharmacodynamic. Pregabalin depresses central nervous system activity across multiple circuits, and spironolactone's diuretic and blood-pressure-lowering effects can compound the dizziness and postural hypotension pregabalin already causes, raising the practical risk of falls, syncope, and impaired alertness.

The FDA-approved labeling for pregabalin (Lyrica, Pfizer) lists CNS depression and additive respiratory depression as recognized risks when pregabalin is co-administered with any CNS-active agent, including those with indirect hemodynamic effects. [1] Spironolactone's prescribing information separately flags volume depletion, hypotension, and electrolyte disturbance as class-level concerns. [2]

Why "Pharmacodynamic" Matters Clinically

A pharmacokinetic interaction changes drug plasma levels. A pharmacodynamic interaction changes drug effects without altering levels. Because plasma concentrations remain in range, standard therapeutic drug monitoring will not flag the problem. The prescriber must anticipate the additive effect manually and counsel the patient explicitly.

CYP and Transporter Profile of Each Drug

Spironolactone is converted hepatically to active metabolites (canrenone, 7-alpha-thiomethylspironolactone) primarily through non-CYP oxidative pathways. [3] Pregabalin is not metabolized by cytochrome P450 enzymes at all; it is excreted renally, largely unchanged, with a renal clearance proportional to creatinine clearance. [4] Neither drug meaningfully inhibits or induces CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at approved doses. P-glycoprotein involvement is not considered clinically significant for either agent. This clean metabolic separation is actually why the interaction is easy to overlook in drug-interaction checkers that rely primarily on enzyme-based algorithms.

How Pregabalin Causes CNS Depression

Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels in the dorsal horn and multiple CNS regions, reducing calcium influx and thereby decreasing the release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. [5] The net effect is broad CNS depression: reduced nociception, anxiolysis, and sedation. In the RELIEF trial comparing pregabalin 150-600 mg/day against placebo in fibromyalgia (N=748), dizziness occurred in 29% of patients on pregabalin versus 9% on placebo, and somnolence occurred in 22% versus 8%. [6]

Dose-Dependent Sedation Spectrum

At doses of 75 mg twice daily (the typical neuropathic pain starting dose), sedation is mild for most adults. At 300-600 mg/day, the sedation profile becomes clinically significant, particularly in older adults or patients with renal impairment, because pregabalin's clearance is tightly coupled to GFR. [4] A patient with a GFR of 30-60 mL/min/1.73 m² requires dose reduction per the FDA label, typically to 50% of the standard dose. [1]

Respiratory Depression Risk

The FDA issued a safety communication in 2019 noting serious breathing difficulties in patients taking gabapentinoids (gabapentin and pregabalin) alongside opioids or other CNS depressants. [7] While spironolactone is not a CNS depressant in the traditional sense, the communication reinforces that prescribers should systematically evaluate any co-administered agent that blunts CNS or respiratory function. Patients with COPD, obesity-related hypoventilation, or obstructive sleep apnea face compounded respiratory risk.

How Spironolactone Contributes to the Interaction

Spironolactone is a competitive antagonist at mineralocorticoid receptors in the distal nephron, reducing sodium reabsorption and potassium excretion. [2] At doses used for hormonal acne (50-200 mg/day) or heart failure (12.5-50 mg/day), it lowers blood pressure modestly and can cause orthostatic hypotension, particularly during the first four to eight weeks of therapy or after dose escalation.

Orthostatic Hypotension as the Shared Risk

Pregabalin independently causes dizziness through vestibular and cerebellar effects. Spironolactone independently causes orthostatic hypotension through volume reduction and vasodilation via anti-androgenic vascular effects. Together, the two mechanisms converge on the same clinical endpoint: a patient who stands up quickly, feels dizzy, and may fall. A 2018 cohort study published in the BMJ examined falls and fracture risk in older adults taking gabapentinoids alongside antihypertensives (N=191,398); the combination was associated with a 24% increase in serious fall events compared to antihypertensive use alone (adjusted hazard ratio 1.24, 95% CI 1.13-1.36). [8] Spironolactone, as a blood-pressure-lowering agent, falls within the antihypertensive class examined in that analysis.

Hyperkalemia: Separate but Concurrent Concern

Spironolactone's potassium-sparing effect creates a distinct risk when co-administered with any drug or supplement that raises serum potassium. Pregabalin itself does not raise potassium. However, patients prescribed pregabalin for diabetic peripheral neuropathy often carry comorbidities (type 2 diabetes, CKD, ACE inhibitor or ARB use) that independently raise potassium. [9] A full medication review is therefore essential. If the patient is already on an ACE inhibitor, ARB, or potassium supplement alongside spironolactone, adding pregabalin does not worsen hyperkalemia directly, but the clinical context demands a baseline potassium check regardless.

In the RALES trial (N=1,663), spironolactone 25 mg/day added to standard heart failure therapy produced serious hyperkalemia (potassium above 6.0 mEq/L) in 2% of patients at one year. [10] At 50-200 mg/day doses used for acne or hirsutism, the potassium elevation risk is dose-proportional and warrants checking serum electrolytes at baseline and four weeks after dose initiation or escalation. [2]

Who Is Most at Risk?

Not every patient combining these two drugs faces the same level of risk. The following framework stratifies risk and should guide prescriber decision-making before co-prescribing.

High-Risk Characteristics

Patients with any three or more of the following characteristics represent the highest-risk group and warrant the most cautious approach, typically starting pregabalin at 25-50 mg twice daily rather than the standard 75 mg twice daily, and scheduling a two-week follow-up call rather than the usual four-week interval.

• Age 65 or older
• Baseline GFR below 60 mL/min/1.73 m²
• History of orthostatic hypotension or syncope
• Current use of one or more additional CNS depressants (opioids, benzodiazepines, muscle relaxants, antihistamines)
• Current use of ACE inhibitor, ARB, or potassium supplement alongside spironolactone
• Systolic blood pressure consistently below 110 mmHg at baseline

Moderate-Risk Characteristics

Patients who are younger adults without renal impairment, on standard acne doses of spironolactone (50-100 mg/day), and taking pregabalin for a self-limited indication (e.g., post-surgical neuropathic pain) are at moderate risk. Standard counseling, a baseline blood pressure check, and a serum potassium at four weeks are generally sufficient.

Lower-Risk Situations

A patient on spironolactone 25 mg/day for mild hirsutism who requires a short pregabalin course (one to two weeks at 75 mg/day for acute neuropathic flare) is at lower absolute risk, but the prescriber should still document the interaction assessment in the chart and provide written fall-prevention counseling.

Monitoring Protocol

Monitoring for this combination should address both the pharmacodynamic CNS risk and the electrolyte risk separately, because they require different tests and different intervals.

Before Starting the Combination

• Measure serum potassium, sodium, creatinine, and GFR. [2]
• Record baseline standing blood pressure after two minutes upright.
• Review the full medication list for other CNS depressants. [1]
• Screen for obstructive sleep apnea using the STOP-BANG questionnaire if the patient is obese (BMI above 30 kg/m²).
• Confirm the pregabalin dose is renally adjusted if GFR is below 60 mL/min/1.73 m². [4]

At Four Weeks

• Repeat serum potassium and creatinine. [9]
• Ask about new dizziness, falls, or excessive daytime sleepiness using a structured symptom review.
• Re-check standing blood pressure.
• If orthostatic drop exceeds 20 mmHg systolic or 10 mmHg diastolic on standing, consider reducing spironolactone dose by 25 mg or pregabalin dose by one increment.

Ongoing Monitoring

For patients on chronic combination therapy, the American Heart Association recommends electrolyte and renal function checks every three to six months for patients on aldosterone antagonists with any co-morbidity affecting potassium homeostasis. [11] Fall-risk re-assessment using the validated Timed Up and Go test is reasonable annually for patients aged 65 or older. [12]

Spironolactone for Acne: Clinical Context

Spironolactone is used off-label for hormonal acne in cisgender women and transgender women at doses of 50-200 mg/day. Its anti-androgenic effect reduces sebaceous gland activity and decreases circulating dihydrotestosterone. A 2023 randomized trial published in NEJM (N=410) compared spironolactone 50-200 mg/day to placebo in women aged 18-45 with moderate-to-severe acne; spironolactone produced a mean reduction in inflammatory lesion count of 49.5% at 24 weeks versus 28.3% with placebo (P<0.001). [13] Pregabalin is not used for acne, but patients with hormonal acne frequently carry comorbid conditions, including premenstrual dysphoric disorder (PMDD), fibromyalgia, generalized anxiety disorder, and neuropathic pain, all of which are recognized pregabalin indications or off-label uses.

Off-Label Prescribing and Interaction Awareness

Because spironolactone's acne indication is off-label, some prescribing occurs outside dermatology and endocrinology clinics, including via telehealth platforms. This context raises the risk of incomplete medication reconciliation. Patients receiving spironolactone for acne through a telehealth provider may separately receive pregabalin from a pain management clinic without automatic communication between the two prescribers. The 2022 ASHP guidelines on medication reconciliation in ambulatory care settings explicitly recommend that all telehealth visits include a standardized medication history review. [14]

Hormonal Acne and the Pain-Anxiety Overlap

Hormonal acne, PMDD, and central sensitization syndromes (including fibromyalgia) share overlapping pathophysiology through dysregulated HPA-axis signaling and inflammatory amplification. Patients with all three conditions simultaneously are plausible candidates for concurrent spironolactone and pregabalin therapy. Recognizing this clinical overlap proactively, rather than waiting for a patient to report a symptom, reduces adverse event risk.

Patient Counseling Points

Clear written counseling is a regulatory and ethical requirement when dispensing interacting drug pairs. The FDA's Medication Guide system and state pharmacy board regulations both support mandatory written disclosure of drug interactions for Schedule V controlled substances, which pregabalin is classified as since 2005. [1]

What to Tell Patients

• Do not drive or operate heavy machinery until you know how the combination affects your alertness. This restriction applies for the first week after starting or increasing pregabalin, and any time the spironolactone dose changes significantly.
• Stand up slowly from sitting or lying positions. Sit on the edge of the bed for 30 seconds before standing.
• Avoid alcohol completely while taking pregabalin. Even one standard drink can substantially worsen sedation.
• Report any new swelling, shortness of breath, confusion, or muscle weakness immediately, as these can indicate electrolyte disturbance or volume overload.
• Do not take extra potassium supplements or eat unusually large quantities of high-potassium foods (bananas, avocados, potassium-containing salt substitutes) without checking with your prescriber.

Fall Prevention Specifics

The CDC's STEADI (Stopping Elderly Accidents, Deaths, and Injuries) program recommends asking patients on three or more medications affecting blood pressure or CNS function about fall history at every visit. [12] Patients on both spironolactone and pregabalin who report even a single fall in the past year should be referred for a formal physical therapy fall-prevention assessment.

Prescriber Decision Checklist

Before co-prescribing spironolactone and pregabalin, confirm each of the following.

1. Renal function is documented and pregabalin dose is adjusted to GFR per FDA label. [1]
2. Baseline serum potassium is below 5.0 mEq/L. [2]
3. No concurrent nephrotoxic agents or potassium-raising drugs are present without deliberate clinical justification.
4. Patient has received written and verbal counseling about sedation, falls, and alcohol avoidance.
5. A follow-up appointment or telehealth check-in is scheduled within two to four weeks.
6. The combination is documented in the chart with an explicit interaction acknowledgment note.

The Endocrine Society's 2023 clinical practice guideline on androgen-related disorders recommends that clinicians prescribing spironolactone for any indication perform a full drug interaction review at initiation and at each dose change, with explicit attention to drugs that affect blood pressure or CNS function. [15]

As the FDA pregabalin prescribing information states directly: "Pregabalin may cause dizziness and somnolence. Accordingly, advise patients not to drive a car, operate complex machinery, or engage in other hazardous activities until they have sufficient experience with pregabalin to know whether it adversely affects their ability to perform these activities." [1] Spironolactone-related hypotension intensifies exactly this advisory.